Trial Profile
A retrospective, monocentric study to investigate mechanisms of elevated serum creatinine in patients receiving vemurafenib for advanced melanoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Sep 2015
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 04 Sep 2015 Status changed from not stated to completed.
- 22 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.